drugset
drugset / Trial / NCT02172235

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

NCT02172235 ↗

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective was to investigate the effect of different doses of BI 10773 on the bioavailability of pioglitazone after multiple oral doses of both drugs

Timeline

Start
2010-04
Primary completion
2010-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule — Oral
Subject Pioglitazone Small molecule — Oral

Indications

No indication recorded.